University of Hong Kong to operate clinical trial hub in Q4

It will serve as a one-stop clinical trial development platform.

The University of Hong Kong’s LKS Faculty of Medicine will operate the Greater Bay Area International Clinical Trial Institute (GBAICTI), which will be fully operational in the fourth quarter.

It will serve as a one-stop clinical trial development platform to coordinate and integrate clinical trial resources in Hong Kong’s public and private sectors.

The institute will operate at the Central Government-Aided Emergency Hospital in the Hetao area upon completion of its temporary office and biobank. It will move into one of the wet laboratory-enabled buildings, which will be completed in the Hong Kong-Shenzhen Innovation and Technology Park.

“Locating the GBAICTI near the Greater Bay Area International Clinical Trial Centre in the Hetao cooperation zone can combine the strengths of Hong Kong and the Greater Bay Area (GBA) to provide efficient services to the healthcare community,” Health Secretary Lo Chung-mau said. 

“It can also encourage them to conduct clinical trials in Hong Kong and the GBA, thereby expediting the translation of research results,” he added. 

The two parks will also coordinate clinical trial work of both to comply with national and international standards.